Expert disagreements, alternative perspectives, and minority opinions.
Semaglutide may be effective, but it treats the individual while leaving the food environment that drives obesity untouched. Critics worry that pharmaceutical success reduces political pressure for structural change.
“Framing obesity primarily as a hormonal deficiency requiring lifelong pharmaceutical intervention shifts responsibility away from systemic factors: the ultra-processed food industry, urban design, and socioeconomic inequality.”
Editorial Context
This perspective argues that GLP-1 agonists create a 'silver bullet' mentality that ignores root causes of metabolic disease. The counter-argument is that patients need treatment now, regardless of upstream policy failures.
Detail
The critique extends to global health equity: if a significant percentage of the world's population becomes dependent on patented biologics for metabolic health, the economic and access implications are enormous. Health economists question the opportunity cost of billions in drug spending versus preventive infrastructure investment.
Suppressing appetite at the neurological level raises questions about eating disorders, loss of food as social bonding, and whether chronic reward-circuit modification carries hidden psychological costs.
“The long-term dampening of reward circuits might subtly diminish pleasure in other non-food-related areas of life over decades of use.”
Editorial Context
Clinical data focuses on the neurobiological benefit of reducing 'cravings' and 'wanting' without blunting baseline hedonic tone. Critics question whether this distinction holds over years of continuous use.
Detail
There is a niche debate around 'pharmacological anhedonia': whether decades of mesolimbic dampening could erode the capacity for pleasure more broadly. This is difficult to study because the effect, if real, would be subtle and slow-developing.
The rebound effect suggests semaglutide suppresses metabolic dysfunction rather than resolving it. If the drug is effectively lifelong, the economic sustainability and access equity of this model deserve scrutiny.
“Patients regain two-thirds of lost weight within a year of stopping. This is a treatment model, not a cure model, and the distinction matters enormously for cost, access, and patient autonomy.”
Editorial Context
STEP extension data confirmed significant weight regain after discontinuation, alongside reversal of cardiometabolic benefits.
Detail
At current pricing, lifelong semaglutide for hundreds of millions of eligible patients globally is a question of pharmaceutical economics as much as medicine. Critics argue this creates 'pharmaceutical entrapment' where stopping treatment means losing benefits.
The evidence base for semaglutide is large but predominantly industry-funded. Independent replication and real-world effectiveness studies would strengthen confidence, particularly for newer indications like MASH and addiction.
“Many of the pivotal trials, including SELECT, SUSTAIN, FLOW, and SOUL, were sponsored by the manufacturer. The healthy user bias in clinical trials means participants are often more motivated and closely monitored than the general population.”
Editorial Context
This is a structural concern about evidence quality, not a claim that the data is fabricated. Real-world adverse events and adherence difficulties may be under-represented in manufacturer-led data.
Detail
Publication bias and the healthy user effect are well-documented in pharmaceutical research. The question is not whether SELECT and SUSTAIN were well-designed (they were) but whether their results fully translate to the broader, less monitored patient population.
At global scale, the physical infrastructure of semaglutide delivery, including single-use pens, needles, refrigeration chains, and peptide synthesis waste, carries environmental costs that are currently excluded from health-economic models.
“Billions of discarded plastic injection pens, cold-chain logistics spanning the globe, and the carbon footprint of large-scale acylated peptide synthesis represent an ecological externality that is rarely factored into the cost-benefit analysis.”
Editorial Context
The environmental burden of semaglutide is proportional to its success: the more patients who use it, the larger the footprint.